Comparing the public health burden of chronic hepatitis C and HIV infection in France.

BACKGROUND/AIMS In France, the prevalence of hepatitis C virus (HCV) exceeds that of HIV, but in the absence of treatment, HIV infection progresses more rapidly than HCV. More HIV-infected patients, however, have received treatment. Using reported public health data in France and natural history models, we applied the back-calculation method to project future mortality from HCV and HIV incorporating current therapies. METHODS The HCV model was based on literature data for the natural history of HCV and reports of hepatocellular carcinoma mortality. The HIV model used estimates from the French Hospital Database on HIV and reported AIDS cases and deaths. RESULTS Peak annual mortality from HIV at 5000 occurred in 1994 and was 1000 in 1998, but HCV mortality likely increased through the 1990s and reached 3000 in 1998. Considering only HCV infections occurring until 1998 and currently available therapy, our model suggested that annual HCV-related mortality would continue to rise and would reach 4500 deaths in 2022. In contrast, AIDS-related deaths began to decrease in 1997. CONCLUSIONS The public health burden of HCV is likely on the rise, while the burden of HIV, given the fairly widespread use of effective medications, may be on the decline. These results may help health policymakers in planning their responses to these epidemics.

[1]  J. Wong,et al.  Simulation of hepatitis C based on a mandatory reporting system , 2002, European journal of gastroenterology & hepatology.

[2]  Kholoud Porter,et al.  Survival after introduction of HAART in people with known duration of HIV-1 infection , 2000, The Lancet.

[3]  R. Brookmeyer,et al.  The Minimum Size of the AIDS Epidemic in the United States , 1986 .

[4]  J. Wong,et al.  Estimating future hepatitis C morbidity, mortality, and costs in the United States. , 2000, American journal of public health.

[5]  H. Gershengorn,et al.  Predicting the unpredictable: Transmission of drug-resistant HIV , 2001, Nature Medicine.

[6]  D. Marquardt.  An Algorithm for Least-Squares Estimation of Nonlinear Parameters , 1963 .

[7]  S. Zou,et al.  Prediction of hepatitis C burden in Canada. , 2000, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[8]  Ron Brookmeyer,et al.  MINIMUM SIZE OF THE ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) EPIDEMIC IN THE UNITED STATES , 1986, The Lancet.

[9]  D Costagliola,et al.  Record-linkage between two anonymous databases for a capture-recapture estimation of underreporting of AIDS cases: France 1990-1993. The Clinical Epidemiology Group from Centres d'Information et de Soins de l'Immunodéficience Humaine. , 2000, International journal of epidemiology.

[10]  Jenny K Griffiths,et al.  Modeling the hepatitis C virus epidemic in France using the temporal pattern of hepatocellular carcinoma deaths , 2002, Hepatology.

[11]  S Chevret,et al.  Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death , 2000, Gut.

[12]  H. El‐Serag,et al.  Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States , 2001, Hepatology.

[13]  P. Rosenberg.  Backcalculation models of age-specific HIV incidence rates. , 1994, Statistics in medicine.

[14]  P. Bedossa,et al.  Natural history of liver fibrosis progression in patients with chronic hepatitis C , 1997, The Lancet.

[15]  Kenneth Koury,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[16]  H. El‐Serag,et al.  Risk factors for the rising rates of primary liver cancer in the United States. , 2000, Archives of internal medicine.

[17]  D. Costagliola,et al.  Time to AIDS from 1992 to 1999 in HIV-1-infected subjects with known date of infection. , 2002, Journal of acquired immune deficiency syndromes.

[18]  J. Bruix,et al.  Impact of HBV, HCV and GBV-C/HGV on hepatocellular carcinomas in Europe: results of a European concerted action , 1998 .

[19]  S. Fan,et al.  Prognostic significance of pathologic features of hepatocellular carcinoma a multivariate analysis of 278 patients , 1995, Cancer.

[20]  Hiv Survival,et al.  Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis , 2000, The Lancet.

[21]  R. Hogg,et al.  Models of survival in HIV infection and their use in the quantification of treatment benefits. , 1998, American journal of epidemiology.

[22]  A. Valleron,et al.  Modeling the hepatitis C virus epidemic in france , 1999, Hepatology.

[23]  S. Arii,et al.  Primary Liver Cancer in Japan , 1992, Springer Japan.

[24]  I. Marschner,et al.  Using time of first positive HIV test and other auxiliary data in back-projection of AIDS incidence. , 1994, Statistics in medicine.

[25]  V. Soriano,et al.  Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel. , 2002, AIDS.

[26]  D Costagliola,et al.  Is the AIDS incubation time changing? A back-calculation approach. , 1999, Statistics in medicine.

[27]  R Brookmeyer,et al.  The analysis of delays in disease reporting: methods and results for the acquired immunodeficiency syndrome. , 1990, American journal of epidemiology.

[28]  A. Muñoz,et al.  Models for the incubation of AIDS and variations according to age and period. , 1996, Statistics in medicine.

[29]  Roel A. Coutinho,et al.  Time from HIV-1 seroconversion to Aids and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis: collaborative Group on Aids incubation and HIV survival including the CASCADE EU concerted action , 2000 .

[30]  J. Desenclos,et al.  Hepatitis C in a French population‐based survey, 1994: Seroprevalence, frequency of viremia, genotype distribution, and risk factors , 1997, Hepatology.

[31]  J. Lundgren,et al.  Highly active antiretroviral therapy and coronary heart disease: the need for perspective , 2001, AIDS.

[32]  J. Kaldor,et al.  Estimating progression to cirrhosis in chronic hepatitis C virus infection , 2001, Hepatology.

[33]  Ian C. Marschner,et al.  A method for estimating the age-specific relative risk of HIV infection from AIDS incidence data , 1993 .

[34]  B. Efron,et al.  A Leisurely Look at the Bootstrap, the Jackknife, and , 1983 .

[35]  J. Piette,et al.  Hepatitis C in France: A national survey in the departments of Internal Medicine and Infectious Diseases , 1998, European Journal of Epidemiology.

[36]  C. Camma',et al.  Natural history of chronic hepatitis C. , 1999, Italian journal of gastroenterology and hepatology.